| Literature DB >> 31772976 |
Takashi Shimokawa1,1, Liqiu Ma1,1, Ken Ando1,1, Katsutoshi Sato1,1, Takashi Imai2.
Abstract
After >60 years since the first treatment, particle radiation therapy (RT) is now used to treat various types of tumors worldwide. Particle RT results in favorable outcomes, especially in local control, because of its biological properties and excellent dose distribution. However, similar to other types of cancer treatment, metastasis control is a crucial issue. Notably, immunotherapy is used for cancer treatment with high risk for recurrence and/or metastasis. These 2 cancer therapies could be ideal, complementary partners for noninvasive cancer treatment. In this review, we will focus on preclinical studies combining particle RT, especially carbon ion RT, and immunotherapy. © Copyright 2016 International Journal of Particle Therapy.Entities:
Keywords: dendritic cell; carbon-ion; immunotherapy; mouse; radiotherapy
Year: 2016 PMID: 31772976 PMCID: PMC6871581 DOI: 10.14338/IJPT-15-00023.1
Source DB: PubMed Journal: Int J Part Ther ISSN: 2331-5180